<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133951</url>
  </required_header>
  <id_info>
    <org_study_id>SMMU20100501</org_study_id>
    <nct_id>NCT01133951</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication to Prevent Gastric Cancer</brief_title>
  <official_title>Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jie-Jun Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is the fourth most common type of cancer and the second leading cause of
      cancer-related death in the world. In China, more than 390,000 new patients are diagnosed
      with gastric cancer and more than 300,000 patients are killed by the terrible disease
      annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is
      highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection
      appears to reduce the risk of gastric cancer. However, several recent controlled
      interventional trials by H. pylori eradication to prevent gastric cancer have yielded
      disappointing results. The exact effect of H.pylori eradication on prevention of gastric
      cancer is unclear up to now. To clarify this problem, the investigators conducted a
      prospective, randomized, double-blind, placebo-controlled, population-based study to
      determine whether H pylori eradication would reduce the incidence of gastric cancer in a
      high-risk population in China.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric cancer incidence</measure>
    <time_frame>10 years</time_frame>
    <description>The incidence of gastric cancer in the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histopathological changes</measure>
    <time_frame>10 years</time_frame>
    <description>The histopathological changes of atrophic gastritis or intestinal metaplasia in the two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3000</enrollment>
  <condition>Helicobacter Infections</condition>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>OAC triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAC triple therapy</intervention_name>
    <description>Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.</description>
    <arm_group_label>OAC triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy registered inhabitants from 10 villages in a high-risk county of gastric
             cancer in China

          -  Age 30-59 years

          -  A willingness to participate in the study as indicated by written informed consent

        Exclusion Criteria:

          -  Severe concomitant illness (eg, severe hypertension, coronary heart disease, diabetes
             mellitus, stroke, asthma, liver cirrhosis, tuberculosis, infectious hepatitis, and
             cardiac, respiratory, hepatic, or renal insufficiency)

          -  Patients with epilepsy or severe mental illness

          -  Previous diagnosis of cancer

          -  A history of esophageal or gastric surgery

          -  Drug abuse and drug dependence

          -  Allergic to omeprazole, amoxicillin, or clarithromycin

          -  Pregnant and lactating women

          -  Previous history of H pylori eradication treatment

          -  A negative 13C-urea breath test (UBT)

          -  A definite indication of H. pylori eradication (eg, gastric or duodenum ulcer)

          -  Dysplasia or carcinoma lesions are found in esophageal or gastric histopathological
             examination

          -  Other factors or conditions might influence the results of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie J Wang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Changzheng Hospital affiliated to Second Military Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xi Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital affiliated to Second Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhao-Lai Hua M.D.</name>
      <address>
        <city>Yangzhong City</city>
        <state>Jiangsu</state>
        <zip>212200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Second Military Medical University</investigator_affiliation>
    <investigator_full_name>Jie-Jun Wang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Infections</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Precancerous Conditions</keyword>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Incidence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

